Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pallavi Rane is active.

Publication


Featured researches published by Pallavi Rane.


Journal of the American College of Cardiology | 2017

PERSISTENCE AND ADHERENCE WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS IN CLINICAL PRACTICE

Dionne Hines; Pallavi Rane; Jeetvan Patel; David J. Harrison; Rolin Wade

Background: Elevated low-density lipoprotein cholesterol (LDL-C) is associated with premature atherosclerotic cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have shown reductions in LDL-C levels in patients uncontrolled by statin and/or ezetimibe therapy.


Journal of the American College of Cardiology | 2017

CARDIOLOGIST PERSPECTIVES IN TREATMENT OF DYSLIPIDEMIA PATIENTS WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS AND OTHER LIPID LOWERING THERAPIES

Pallavi Rane; Jeetvan Patel; David J. Harrison; Hollie Bailey; Andrea Leith; James Piercy; Jason Shepherd

Background: The 2013 ACC/AHA guidelines recommend high intensity statins for all high risk patients to reduce the risk of subsequent cardiovascular events. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) were introduced in 2015 as adjunctive therapy for patients needing additional


Journal of the American College of Cardiology | 2017

CHARACTERISTICS OF PATIENTS APPROVED AND DENIED ACCESS TO PCSK9I THERAPY BY PAYERS

Seth J. Baum; Chi-Chang Chen; Pallavi Rane; Jeetvan Patel; Juan Maya; David J. Harrison; Nicole Yurgin; Rolin Wade


American Journal of Cardiovascular Drugs | 2018

Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors

Pallavi Rane; Jeetvan Patel; David J. Harrison; Jason Shepherd; Andrea Leith; Hollie Bailey; James Piercy


Value in Health | 2018

Caregiver Burden Among Individuals Providing Informal Caregiving to Survivors of Major Adverse Cardiac Event (MACE): A Systematic Review

S Bhattacharjee; T Gallo; Jeetvan Patel; David J. Harrison; Pallavi Rane


Value in Health | 2018

History of Lipid Lowering Therapy and Cardiovascular Medication Use Among Patients Initiating PCSK9 Inhibitors in the United States

Rolin L. Wade; Dionne M. Hines; Pallavi Rane; Jeetvan Patel; David J. Harrison


Journal of Clinical Lipidology | 2018

Hospital Readmissions for an Acute Cardiac Event After Hospitalization for Atherosclerotic Cardiovascular Disease

Brian Boatman; Barbara H. Johnson; Pallavi Rane; Stefan DiMario; Jeetvan Patel; Donna McMorrow; David J. Harrison; Machaon Bonafede


Value in Health | 2017

Predictive Analysis for Identifying Patient Characteristics Associated with Primary Medication Nonadherence for Lipid Lowering Therapies

Jw Hill; Pallavi Rane; Dionne M. Hines; Jeetvan Patel; David J. Harrison; Rolin L. Wade


Value in Health | 2017

Short-Term Direct And Indirect Cost Burden of Cardiovascular Events In Patients With A History of Atherosclerotic Cardiovascular Disease In The US

Barbara H. Johnson; Machaon Bonafede; Pallavi Rane; Jeetvan Patel; David J. Harrison


Journal of the American College of Cardiology | 2017

CLINICAL CHARACTERISTICS OF EARLY ADOPTERS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS (PCSK9I)

Machaon Bonafede; Lorena Lopez-Gonzalez; Pallavi Rane; Jeetvan Patel; David J. Harrison

Collaboration


Dive into the Pallavi Rane's collaboration.

Researchain Logo
Decentralizing Knowledge